Multimodal therapy for chronic tinnitus.
From 2001 to 2006, we performed a retrospective study of patients suffering from chronic unilateral or bilateral tinnitus that was previously ineffectively treated by oral drugs [betahistine (Betaserc), extract of Ginkgo biloba (EGb 761), tanakan (Tebokan), and cinnarizine-dimenhydrinate (Arlevert), singly or in combination]. We divided 150 tinnitus patients (80 men, 70 women) into seven treatment groups. Treatments consisted of application of intravenous pentoxifylline, lidocaine, or vinpocetine (Cavinton) and combination of these agents with physiotherapy and soft laser. Mean duration (+/- standard deviation) of tinnitus in these patients was 7.4 +/- 6.0 years; their mean age was 55.6 +/- 12.5 years. The aim of our study was to compare treatment modalities and define their effectiveness for tinnitus relief. The most effective treatment was defined as a combination of Cavinton and physiotherapy. We evaluated pure lidocaine infusion therapy as ineffective. None of the treatment modalities had an objective correlate of improvement, though improvement was reported by a visual analog scale.
Hahn
Ales
A
Ear, Nose, and Throat Department, Third Medical Faculty, Charles University, Prague, Czech Republic. hahn@fnkv.cz
Radkova
Lenka
L
Achiemere
Gabriela
G
Klement
Vladislav
V
Alpini
Dario
D
Strouhal
Jaroslav
J
D000328:Adult; D000368:Aged; D001621:Betahistine / Q000627:therapeutic use; D002908:Chronic Disease; D002936:Cinnarizine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004111:Dimenhydrinate / Q000627:therapeutic use; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D020441:Ginkgo biloba; D006801:Humans; D008012:Lidocaine / Q000627:therapeutic use; D028022:Low-Level Light Therapy; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use; D026741:Physical Therapy Modalities; D010936:Plant Extracts / Q000627:therapeutic use; D012189:Retrospective Studies; D014012:Tinnitus / Q000534:rehabilitation*; D014748:Vinca Alkaloids / Q000627:therapeutic use; D000096983:Ginkgo Extract
D001621:Betahistine; D002936:Cinnarizine; D004111:Dimenhydrinate; D004338:Drug Combinations; D008012:Lidocaine; D010431:Pentoxifylline; D010936:Plant Extracts; D014748:Vinca Alkaloids; C410867:cinnarizine, dimenhydrinate drug combination; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract; C013983:vinpocetine